In a new “blueprint” document, the CGPA has called for investment in Canada’s domestic generic pharmaceutical infrastructure to bolster its manufacturing and supply capabilities, as well as urging an enhanced international role and a local stockpile of essential drugs.

In an attempt to strengthen the US generic drug supply chain and reduce dependence on certain countries for supply, the AAM has proposed a policy framework “blueprint” that requires government purchasing commitments in exchange for industry manufacturing expansion.

Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.